

COMMITTEE ON FINANCE & ADMINISTRATION

財務及行政委員會

The Committee on Finance and Administration undertakes to monitor the finance, administration and investment affairs of the Board, and I am honoured to report the works of this Committee.

In 2019, the financial position of the Board was stable and healthy. Total levy income decreased by 8.51% to \$336.28 million when compared with the value of \$367.55 million in last year. The levies from the public sector decreased by 16.30% to \$162.37 million, and that from the private sector increased by 0.18% to \$173.74 million. On the other hand, levies from the quarry industry increased from \$0.13 million to \$0.17 million.

Total investment income was \$72.95 million, which showed an increase of \$15.64 million or 27.29% compared with \$57.31 million of last year. The interest income of certificate of deposits, bonds and fixed deposits increased by 32.16% or \$13.62 million to \$55.97 million. The dividend income increased from \$14.96 million to \$16.98 million.

On the total expenditure, it increased by 0.51% to \$290.76 million. Total compensation of \$213 million showed a decrease of \$0.46 million or 0.22% from 2018.

Moreover, a total of \$48.67 million was spent for prevention, research and rehabilitation, which was \$4.71 million or 10.71% more than 2018. The increase was partly due to the larger number of rehabilitation exercises taken by patients in community rehabilitation centres, as well as the payment made to the Hospital Authority for the new rehabilitation programme launched in December 2019.

To sum up, \$268.42 million or 92.32% of the total expenditure of the Board were paid as compensation, medical examination, research, prevention and rehabilitation for the benefit of patients and workers.

Besides, a total of \$0.64 million was spent for information technology meeting the maintenance and recurrent requirements of the Board. Another sum of \$1.12 million was spent for hardware and systems software which were capitalised respectively as fixed assets and intangible assets of the Board.

財務及行政委員會承擔監督委員會的財務、行政及投資事宜。本人很榮幸向各位匯報委員會的工作報告。

2019年度基金委員會的財務狀況既穩定又健康，是年度共收到三億三千六百二十八萬元之徵款，相比去年三億六千七百五十五萬元減少了8.51%。從公共工程項目收到徵款共一億六千二百三十七萬元，比去年減少了16.30%，而私人工程項目則錄得徵款增加了0.18%，共收到一億七千三百七十四萬元。另一方面，從石礦業收到的徵款則由上年度之十三萬元增加至十七萬元。

整體投資收入方面，共收到七千二百九十五萬元，相比去年五千七百三十一萬元，增加一千五百六十四萬元或27.29%。從存款證、債券及銀行定期存款所得的利息收入共五千五百九十七萬元，較上年度收入增加一千三百六十二萬元或32.16%。而股息收入由上年度之一千四百九十六萬元增加至一千六百九十八萬元。

支出方面，是年度總開支比上年增加0.51%，共二億九千零七十六萬元。支付肺塵埃沉着病及間皮瘤病人之各項補償開支共二億一千三百萬元，比2018年減少0.22%或四十六萬元。

除補償開支外，基金委員會亦運用了四千八百六十七萬元進行各項預防、研究及復康工作，比上年增加四百七十一萬元，增幅達10.71%，其中所增加開支，部份是因有較多病人在社區復康中心進行復康運動，而同時亦需支付醫院管理局2019年12月啟動的新復康計劃涉及的支出。

總括而言，用於補償、判傷、研究、預防及復康工作的支出共二億六千八百四十二萬元，佔總開支之92.32%。

除此之外，其中涉及基金委員會資訊科技的維修及經常性開支共六十四萬元。另外，一百一十二萬元則投放在電腦的硬件及系統的軟件上，該些支出分別被撥作為固定資產及無形資產。

COMMITTEE ON FINANCE & ADMINISTRATION

財務及行政委員會



The surplus of income over expenditure for the year was \$134.44 million, which was \$19 million or 12.38% less than the previous year. The balance of accumulated fund as at end of the year was \$2,730.28 million.

Regarding the investment of reserves, about 85% of the surplus funds were placed on certificate of deposits, bonds and fixed deposit at short to long-term fixed rates in order to ensure a relatively stable interest income. The certificate of deposits and bonds will be held to maturity, while the remaining 15% of the surplus funds were invested in listed shares and the Tracker Fund for dividend income and long-term investment purposes. In 2019, the global financial markets remained very volatile, and thereby increased the risk of investment. The Committee had been closely monitoring the investment portfolios and achieved satisfactory results on investments.

In June 2019, the Board submitted its annual report in 2018 for tabling in the Legislative Council. The Estimates of Income and Expenditure together with the Yearly Programme for 2020 were also submitted in December 2019 for approval by the Government in accordance with the provision of the Pneumoconiosis and Mesothelioma (Compensation) Ordinance (PMCO).

As the authorized paying agent of the Pneumoconiosis Ex Gratia Fund ("the Fund"), the Board presented the Fund's interim and final reports together with the financial statements for the year ended 31 March 2019 which were audited by the Director of Audit and approved by the Government.

Finally, we would like to thank members for their outstanding efforts and contributions in advising and directing the finance, administration and investment affairs of the Board.

基金委員會是年度錄得盈餘共一億三千四百四十四萬元，比上年減少一千九百萬元，即12.38%。於年終結算日累積基金為二十七億三千零二十八萬元。

關於儲備的投資策略，委員會將大約85%之儲備基金盈餘用於購買存款證、債券及作短至長期之定期存款，以確保較穩定之利息收入。存款證及債券會持有至到期日，而其餘15%之基金盈餘會投資股票及盈富基金，以收取股息及作長線投資。2019年環球投資市場仍極為動盪，大大增加投資風險，委員會繼續密切監察各投資項目，並得到滿意的投資結果。

基金委員會於2019年6月提交了二零一八年度之年報，以提交立法會；亦於12月按《肺塵埃沉着病及間皮瘤(補償)條例》(肺塵病條例)規定提交了二零二零年度之財政預算與全年工作計劃供香港特別行政區政府審批。

作為政府委託之肺塵埃沉着病特惠金付款人，基金委員會於年內向香港特別行政區政府提交了中期報告、全年報告及截至二零一九年三月三十一日財政年度經審計署署長核實及政府審批之財務報告。

最後，我們衷心感謝各位委員在財務、行政及投資事宜的建議、指導及所作出的卓越貢獻。